Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
週一關注Enerpac工具集團、Singular Genomics Systems和3只股票
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
今天早上美國股市期貨略有上漲，今天可能受到投資者關注的一些股票如下:
- Wall Street expects Enerpac Tool Group Corp. (NYSE:EPAC) to report quarterly earnings at 47 cents per share on revenue of $153.20 million after the closing bell. Enerpac Tool Group shares gained 1.9% to $39.22 in after-hours trading.
- Singular Genomics Systems, Inc. (NASDAQ:OMIC) reported a 1-for-30 reverse stock split. Singular Genomics shares fell 9.3% to $0.3180 in the after-hours trading session.
- Analysts are expecting Beyond Air, Inc. (NASDAQ:XAIR) to post a quarterly loss at $0.48 per share on revenue of $747.20 thousand. The company will release earnings after the markets close. Beyond Air shares gained 8.1% to $1.34 in after-hours trading.
- 華爾街預計 Enerpac Tool Group Corp. (紐交所: EPAC) 將在收盤後以每股47美分的收益和1.532億美元的營業收入發佈季度業績。 Enerpac Tool Group 股票在盤後交易中漲1.9%至39.22美元。
- Singular Genomics Systems, Inc. (納斯達克: OMIC) 報告進行1比30的股票回購拆分。 Singular Genomics 股票在盤後交易中下跌9.3%，至0.3180美元。
- 分析師預計 Beyond Air, Inc. (納斯達克: XAIR) 將在每股0.48美元的虧損和74.72萬美元的營業收入後發佈季度業績。該公司將在市場收盤後發佈業績。 Beyond Air 股票在盤後交易中漲8.1%，至1.34美元。
Check out our premarket coverage here
請查看我們的盤前報道。
- Iteris, Inc. (NASDAQ:ITI) filed for a $150 million mixed securities shelf offering. Iteris shares fell 1.2% to $4.0201 in the after-hours trading session.
- Stoke Therapeutics, Inc. (NASDAQ:STOK) said its Chief Operating Officer Huw Nash will step down, but will continue as Chief Business Officer, effective June 18. Stoke Therapeutics shares fell 3.6% to close at $14.23 on Friday.
- Iteris, Inc. (納斯達克: ITI) 提出了1.5億美元的混合證券貨架招股說明書。Iteris股票在盤後交易中下跌1.2%，至4.0201美元。
- Stoke Therapeutics, Inc. (納斯達克: STOK) 表示其首席運營官Huw Nash將退任，但將繼續擔任首席業務官，自6月18日起生效。 Stoke Therapeutics股票在上週五下跌3.6%，收於14.23美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。